Sorafenib Zentiva is indicated for the treatment of hepatocellular carcinoma
Renal cell carcinoma
Sorafenib Zentiva is indicated for the treatment of patients with advanced renal cell carcinoma who have failed prior interferon-alpha or interleukin-2 based therapy or are considered unsuitable for such therapy.
The recommended dose of Sorafenib in adults is 400 mg sorafenib (two tablets of 200 mg) twice daily (equivalent to a total daily dose of 800 mg).
Treatment should continue as long as clinical benefit is observed or until unacceptable toxicity occurs.
The safety and efficacy of Sorafenib in children and adolescents aged < 18 years have not yet been established.